Assess Fibrin in Brains With AD/ADRD

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT05336695
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
55 Years - 90 Years
Healthy Volunteers
Accepted

Interventions

  • PET/MR Imaging — DIAGNOSTIC_TEST
    PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol
  • 64Cu-FBP8 — DRUG
    Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center

Study Details

The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.

Key Dates

Start date
Mar 29, 2022
Status verified
Oct 2025
Primary completion
Sep 28, 2026
Completion
Sep 28, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Cognitively Normal Subjects and ADRD subjects
    Cognitively Normal Subjects and ADRD subjects

Primary Outcome Measure

Concentration of fibrin in the brains of ADRD subjects and healthy controls [ Time Frame: baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02115
Ciprian Catana, MD, PhD
[email protected]
617-643-4885
Ciprian Catana, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Massachusetts General Hospital· Boston, MA

Related Studies